Clinical Trials Directory
We are doing this study to find out the effects, good or bad, of an investigational drug called RO7200220 (the study drug) for participants with uveitic macular edema. This condition is caused by uveitis, and it is when fluid builds up in the retinal layers and causes swelling that can impair vision.
We are doing this study to look at different tissues that could contribute to chronic pain and obesity.
We are doing this study to collect data and samples to store them for future research.
We hope this data and samples will lead to improved treatment of patients who are seriously ill or have been injured.
We are doing this study to find out if a new type of assessment works well for middle-aged and older adults with sickle cell disease (SCD). We want to see if this assessment is useful in detecting changes in health. We hope the assessment can provide useful information to help improve the quality of life for adults with sickle cell disease.
We are doing this study to find out how see how easy or difficult it is to complete a hybrid (virtual and in-person) personalized exercise training program for older adults with sickle cell disease. The virtual training sessions will be done primarily on Zoom. This research is important to determine ways to improve movement capacity, heart health, strength, and quality of life in older adults living with sickle cell disease.
We are doing this study to find out if an experimental drug called lasofoxifene (the study drug) is a safe and effective option for breast cancer. We want to see if the study drug combined with another drug called abemaciclib has better results than treatment with abemaciclib plus fulvestrant.
We want to learn more about people with spina bifida and their risk of developing dementia if they have the APOE e4 gene.
We are doing this study to find out the highest dose of a drug called olaparib that is safe to give at
the same time as stereotactic radiosurgery (SRS). We also want to see if we can lessen the chance of having your cancer return by following the olaparib + SRS treatment with a combination of chemotherapy and a drug called durvalumab.